IMPI: No Immunotherapy Benefit in Tuberculous PericarditisIMPI: No Immunotherapy Benefit in Tuberculous Pericarditis
Although prednisolone might be appropriate in some patients, the authors propose, neither the glucocorticoid nor M indicus pranii immunotherapy improved survival in the 1400-patient trial. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 8, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news
ESC: Mixed Results with Steroids in TB Pericarditis
BARCELONA (MedPage Today) -- Adding steroids to anti-tuberculosis treatment for patients with tuberculous pericarditis can reduce the risk of complication and the resulting hospital admission, but adding prednisolone to tuberculosis treatment did not reduce the risk of death, researchers said here. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 3, 2014 Category: Primary Care Source Type: news
prednisolone (Flo-Pred, Pediapred, Orapred, Orapred ODT)
Title: prednisolone (Flo-Pred, Pediapred, Orapred, Orapred ODT)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/7/2014 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - August 7, 2014 Category: Rheumatology Source Type: news
Bayer starts patient enrolment in Phase III prostate cancer trial
Bayer HealthCare has started patient enrolment in a new Phase III trial of radium-223 dichloride (radium-223, Xofigo) in combination with abiraterone acetate and prednisone/prednisolone to treat asymptomatic or mildly symptomatic chemotherapy-naïve p… (Source: Drug Development Technology)
Source: Drug Development Technology - April 4, 2014 Category: Pharmaceuticals Source Type: news
Bifunctional Antibody Fragment-Based Fusion Proteins for the Targeted Elimination of Pathogenic T-Cell Subsets
Pathogenic effector T cells are key contributors to autoimmune diseases such as systemic lupus erythematosus (SLE). General inhibition of T cells using, e.g., methotrexate, prednisolone, or TNF blockers, has prominent therapeutic effects frequently at the cost of severe long-term side effects and toxicity. Therefore, targeted strategies that can selectively inhibit or eliminate pathogenic T cells are sought after as a new approach to safely block perpetual inflammatory T-cell responses and inhibit concomitant progressive tissue destruction. Of particular interest in this respect is the use of the so-called single-chain fra...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news
Prednisolone or Dexamethasone for Acute Asthma ExacerbationsPrednisolone or Dexamethasone for Acute Asthma Exacerbations
Which medication is most effective in the management of acute asthma exacerbations in children? Archives of Disease in Childhood (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2013 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news
Severe Alcoholic Hepatitis: Combination Therapy No Better
(Ivanhoe Newswire) –Four weeks of treatment with a combination of the drug pentoxifylline and the corticosteroid prednisolone did not improve survival compared with just prednisolone in 270 patients with severe alcoholic hepatitis. (Source: Medical Headlines From Ivanhoe.com)
Source: Medical Headlines From Ivanhoe.com - September 12, 2013 Category: Consumer Health News Source Type: news
Combination therapy for severe alcoholic hepatitis does not result in improved survival
Four weeks of treatment with a combination of the drug pentoxifylline and the corticosteroid prednisolone did not improve 6-month survival compared with prednisolone alone in 270 patients with severe alcoholic hepatitis, according to a study in the September 11 issue of JAMA. Treatment of severe forms of alcoholic hepatitis is extremely challenging because of the poor outcome. European and U.S. guidelines recommend the use of prednisolone or pentoxifylline in patients with severe alcoholic hepatitis... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 11, 2013 Category: Consumer Health News Tags: Liver Disease / Hepatitis Source Type: news
LCNDG Rapid Review: Bortezomib for first-line, transplant unsuitable multiple myeloma
Source: London Cancer New Drugs Group
Area: Evidence > Drug Specific Reviews
There are no trials directly comparing bortezomib, melphalan, and prednisolone versus thalidomide-based regimens in patients with multiple myeloma who are not able to receive high-dose therapy and stem cell transplant.
The phase III open-label randomised control trial investigating melphalan-prednisolone (control arm) against bortezomib-melphalan-prednisolone (bortezomib arm) reported a median time to progression of 24 months in the bortezomib arm and 16.6 months in the control arm (hazard ratio 0.48; P<0.001). The response cou...
Source: NeLM - Drug Specific Reviews - February 12, 2013 Category: Drugs & Pharmacology Source Type: news
Abiraterone (Zytiga®) approved in the EU for treatment of metastatic castration-resistant prostate cancer prior to chemotherapy
Source: BioSpace
Area: News
According to BioSpace, the European Commission (EC) has approved an extension to the license of abiraterone to include its use, in combination with prednisone or prednisolone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. Abiraterone has until now has been approved only for use in men with mCRPC whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
The approval follows a...
Source: NeLM - News - January 14, 2013 Category: Drugs & Pharmacology Source Type: news
RCT: Immunosuppression for progressive membranous nephropathy
Source: Lancet
Area: News
There is considerable uncertainty regarding the optimum therapeutic management of idiopathic membranous nephropathy which can lead to end-stage renal disease in more than 20% of patients. The benefits of immunosuppressive therapy have been demonstrated in some patients, but not in those patients with declining renal function.
To investigate therapeutic options in this subset, this randomised controlled trial, undertaken in 37 UK renal units, recruited adult patients with biopsy-proven idiopathic membranous nephropathy, a plasma creatinine concentration of less than 300 micromol/L, and...
Source: NeLM - News - January 9, 2013 Category: Drugs & Pharmacology Source Type: news
